Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
8.93
+0.09 (1.02%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Entrada Therapeutics stock have an average target of 25.67, with a low estimate of 20 and a high estimate of 29. The average target predicts an increase of 187.46% from the current stock price of 8.93.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Entrada Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +123.96% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +123.96% | Feb 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +123.96% | Feb 4, 2025 |
| Roth MKM | Roth MKM | Strong Buy Initiates $29 | Strong Buy | Initiates | $29 | +224.75% | Dec 5, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +213.55% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
37.42M
from 210.78M
Decreased by -82.25%
Revenue Next Year
28.78M
from 37.42M
Decreased by -23.10%
EPS This Year
-3.48
from 1.68
EPS Next Year
-3.79
from -3.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.2M | 59.2M | 59.2M | ||
| Avg | 37.4M | 28.8M | 32.3M | ||
| Low | 19.6M | n/a | 6.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -71.9% | 58.3% | 105.9% | ||
| Avg | -82.2% | -23.1% | 12.4% | ||
| Low | -90.7% | - | -76.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -3.17 | -3.32 | -3.70 |
| Avg | -3.48 | -3.79 | -4.09 |
| Low | -4.03 | -4.41 | -4.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.